FOLD vs. HALO, RGEN, MDGL, IONS, ALKS, BCRX, LGND, CLDX, MNKD, and INVA
Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Halozyme Therapeutics (HALO), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), BioCryst Pharmaceuticals (BCRX), Ligand Pharmaceuticals (LGND), Celldex Therapeutics (CLDX), MannKind (MNKD), and Innoviva (INVA). These companies are all part of the "biotechnology" industry.
Amicus Therapeutics vs.
Halozyme Therapeutics (NASDAQ:HALO) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends.
Amicus Therapeutics received 3 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 72.81% of users gave Amicus Therapeutics an outperform vote while only 69.10% of users gave Halozyme Therapeutics an outperform vote.
Halozyme Therapeutics presently has a consensus price target of $61.90, indicating a potential upside of 15.12%. Amicus Therapeutics has a consensus price target of $16.22, indicating a potential upside of 165.50%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Amicus Therapeutics is more favorable than Halozyme Therapeutics.
Halozyme Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
Halozyme Therapeutics has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Halozyme Therapeutics has a net margin of 43.74% compared to Amicus Therapeutics' net margin of -10.62%. Halozyme Therapeutics' return on equity of 157.78% beat Amicus Therapeutics' return on equity.
In the previous week, Halozyme Therapeutics had 4 more articles in the media than Amicus Therapeutics. MarketBeat recorded 10 mentions for Halozyme Therapeutics and 6 mentions for Amicus Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.83 beat Amicus Therapeutics' score of -0.59 indicating that Halozyme Therapeutics is being referred to more favorably in the media.
97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.4% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Halozyme Therapeutics beats Amicus Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Amicus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amicus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FOLD) was last updated on 6/10/2025 by MarketBeat.com Staff
